Researchers highlight gaps in disclosure of payments between radiologists and AI device manufacturers, urging greater transparency to ensure ethical AI deployment.
Key Details
- 1Many AI-enabled radiology devices have been FDA cleared in the past decade.
- 2Researchers found that over 90% of these device manufacturers reported zero payments to healthcare professionals or teaching hospitals (2017–2023).
- 3This is attributed to regulatory gaps and ambiguities in AI device classification and reporting requirements.
- 4Recent commenters on FDA AI regulations often failed to disclose industry ties.
Why It Matters
As AI becomes more integral to radiology, undisclosed relationships between clinicians and developers could bias research, product adoption, and regulatory processes. Strengthening transparency safeguards patient trust and ensures objective evaluation of new technologies.
Source
Radiology Business
Related News
•Radiology Business
Harrison.ai Receives FDA Breakthrough Status for Imaging AI Device
Harrison.ai has been awarded three FDA breakthrough device designations for its imaging AI solutions, including a tool for obstructive hydrocephalus triage.
•AuntMinnie
Experts Call for Stricter FDA Standards in Radiology AI Validation
Dana-Farber experts recommend actionable steps to enhance the rigor and transparency of FDA validation standards for radiology AI software.
•AuntMinnie
Head-to-Head Study Evaluates AI Accuracy in Fracture Detection on X-Ray
A prospective study compared three commercial AI tools for fracture detection on x-ray, showing moderate-to-high accuracy for simple cases but weaker performance in complex scenarios.